Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1983 1
1991 1
1994 2
1996 4
1997 2
1998 2
1999 2
2000 6
2001 10
2002 6
2003 9
2004 13
2005 10
2006 7
2007 8
2008 9
2009 9
2010 10
2011 10
2012 13
2013 13
2014 12
2015 21
2016 22
2017 17
2018 26
2019 28
2020 51
2021 49
2022 52
2023 42
2024 36
2025 54

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Results by year

Filters applied: . Clear all
Page 1
Defining the clinical course of multiple sclerosis: the 2013 revisions.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Lublin FD, et al. Among authors: inglese m. Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28. Neurology. 2014. PMID: 24871874 Free PMC article.
Art therapy for Parkinson's disease.
Cucca A, Di Rocco A, Acosta I, Beheshti M, Berberian M, Bertisch HC, Droby A, Ettinger T, Hudson TE, Inglese M, Jung YJ, Mania DF, Quartarone A, Rizzo JR, Sharma K, Feigin A, Biagioni MC, Ghilardi MF. Cucca A, et al. Among authors: inglese m. Parkinsonism Relat Disord. 2021 Mar;84:148-154. doi: 10.1016/j.parkreldis.2021.01.013. Epub 2021 Jan 23. Parkinsonism Relat Disord. 2021. PMID: 33526323 Free article. Clinical Trial.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial.
Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Motl RW, Rocca MA, Sandroff BM, Salter A; CogEx Research Team. Feinstein A, et al. Among authors: inglese m. Lancet Neurol. 2023 Oct;22(10):912-924. doi: 10.1016/S1474-4422(23)00280-6. Lancet Neurol. 2023. PMID: 37739574 Free article. Clinical Trial.
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. Androdias G, et al. Among authors: inglese m. Brain. 2025 May 13;148(5):1459-1478. doi: 10.1093/brain/awae409. Brain. 2025. PMID: 39707906 Free PMC article. Review.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
Calabrese M, Preziosa P, Scalfari A, Colato E, Marastoni D, Absinta M, Battaglini M, De Stefano N, Di Filippo M, Hametner S, Howell OW, Inglese M, Lassmann H, Martin R, Nicholas R, Reynolds R, Rocca MA, Tamanti A, Vercellino M, Villar LM, Filippi M, Magliozzi R. Calabrese M, et al. Among authors: inglese m. Ann Neurol. 2024 Jul;96(1):1-20. doi: 10.1002/ana.26913. Epub 2024 Apr 3. Ann Neurol. 2024. PMID: 38568026 Review.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis.
Benamar M, Contini P, Schmitz-Abe K, Lanzetta O, Getachew F, Bachelin C, Leyva Castillo JM, Wang M, Oktelik FB, Perrot O, Batamack Y, Arbag SN, Stephen-Victor E, Harb H, Agrawal PB, Louapre C, Ivaldi F, Uccelli A, Inglese M, Angelini C, Zujovic V, De Palma R, Chatila TA. Benamar M, et al. Among authors: inglese m. Immunity. 2025 Nov 11;58(11):2753-2768.e6. doi: 10.1016/j.immuni.2025.09.007. Epub 2025 Oct 2. Immunity. 2025. PMID: 41043415
474 results